查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1632610

全球多核苷酸注射劑市場：市場規模、佔有率和趨勢分析（按應用、最終用途、地區和細分市場，2025-2030 年）

Polynucleotides Injectable Market Size, Share & Trends Analysis Report By Application (Eyes, Lips, Forehead, Jawline & Cheekbones), By End-use (MedSpas, Aesthetic & Cosmetic Centers), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

多核苷酸注射劑市場規模及趨勢：

2024 年全球多核苷酸注射劑市場價值估計為 1.276 億美元，預計 2025 年至 2030 年期間複合年成長率為 15.1%。

主要是生物技術的進步推動了市場成長，以及對活膚、個人化醫療和研發（R&D）投資的需求不斷成長。根據 PMTA 雜誌 2024 年 3 月發表的一篇論文，多核苷酸注射因其對皮膚、頭髮和其他組織的有益作用而成為美容醫學領域的焦點，正如這篇綜合評論中所討論的那樣。

對先進的活膚治療的需求不斷成長是多核苷酸注射劑行業發展的主要驅動力。隨著人們尋求更有效的解決方案來解決細紋、皺紋和皮膚鬆弛等老化徵兆，人們對多核苷酸等新型注射療法的興趣激增。例如，最近發表在《皮膚病學治療》雜誌上的一項研究發現，多核苷酸注射可以改善 30 多歲和 40 多歲患者的膚色、細紋、皮膚彈性和水分含量。

對個人化醫療的日益關注也促進了市場的成長。由於醫療保健提供者和患者都尋求客製化的皮膚恢復方法，多核苷酸刺激人體天然膠原蛋白的產生和細胞再生的能力使其成為受歡迎的選擇。這一趨勢在個人化美容需求日益成長中表現得尤為明顯，預計市場將繼續擴大。

最後，數位成像和自動注射系統等創新技術的整合正在進一步推動多核苷酸注射劑產業的發展。這些進步提高了多核苷酸注射的準確性、一致性和安全性，使其對醫療保健提供者和患者更具吸引力。隨著美容產業的不斷發展，預計採用最尖端科技將繼續成為多核苷酸注射劑產業發展的關鍵驅動力。例如，2022 年，倫敦脈衝光診所將推出 Croma 的 PhilArt，這是一種創新的多核苷酸輸液治療，可顯著增加皮膚水分、改善彈性並刺激天然膠原蛋白的產生。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 多核苷酸注射劑市場：促進因素、趨勢和範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 多核苷酸注射劑市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第4章 多核苷酸注射劑市場：按應用分類的估計和趨勢分析

  • 按應用分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球多核苷酸注射劑市場應用前景
  • 市場規模預測及趨勢分析（2018-2030年）
    • 眼睛
    • 嘴唇
    • 數量
    • 下顎線和顴骨
    • 其他

5. 多核苷酸注射劑市場：依最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球多核苷酸注射劑市場前景（按最終用途）
  • 市場規模預測及趨勢分析（2018-2030年）
    • 醫療水療
    • 美容美髮中心
    • 醫院

6. 多核苷酸注射劑市場：區域估計和趨勢分析

  • 按地區分類的市場佔有率分析（2024 年和 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2024年）
    • PHARMA RESEARCH
    • BIOPLUS CO., LTD.
    • LG Chem
    • AMEELA
    • Mastelli
    • Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
    • Promoitalia Laboratories
    • Fox Pharma
    • BR Pharm
    • DermFocus
Product Code: GVR-4-68040-361-6

Polynucleotides Injectable Market Size & Trends:

The global polynucleotides injectable market size was estimated at USD 127.6 million in 2024 and is projected to grow at a CAGR of 15.1% from 2025 to 2030. Technological advancements in biotechnology primarily drive market growth, as do the increasing demand for skin rejuvenation, personalized medicine, and investments in research and development (R&D). According to an article published by PMTA Journal in March 2024, polynucleotide injections gained prominence in aesthetic medicine due to their beneficial effects on skin, hair, and other tissues, as explored in this comprehensive review.

The growing demand for advanced skin rejuvenation treatments is a primary driver of the polynucleotides injectable industry. As individuals seek more effective solutions to address signs of aging, such as fine lines, wrinkles, and skin laxity, the interest in novel injectable treatments such as polynucleotides has surged. For instance, a recent study published in the journal Dermatologic Therapy found that polynucleotide injections improved skin tone, fine lines, skin elasticity, and hydration in patients in their 30s and 40s.

The increasing focus on personalized medicine also contributed to the growth of the market. As healthcare providers and patients alike seek customized approaches to skin rejuvenation, polynucleotides' ability to stimulate the body's natural collagen production and cellular regeneration has made them a popular choice. This trend is particularly evident in the rising demand for personalized aesthetic treatments, which is expected to continue expanding the market.

Finally, integrating innovative technologies, such as digital imaging and automated injection systems, has further propelled the polynucleotides injectable industry. These advancements improved polynucleotide injections' precision, consistency, and safety, making them more appealing to healthcare providers and patients. As the aesthetic industry continues to evolve, incorporating cutting-edge technologies is expected to remain a vital driver of the polynucleotide injectable industry. For instance, in 2022, Pulse Light Clinic in London is introducing PhilArt by Croma, an innovative polynucleotide injection treatment recognized for significantly enhancing skin hydration, boosting elasticity, and stimulating natural collagen production - a pioneering advancement in skin rejuvenation.

Global Polynucleotides Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polynucleotides injectable market report based on application, end-use, and region:

  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Eyes
  • Lips
  • Forehead
  • Jawline & Cheekbones
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • MedSpas
  • Aesthetic & Cosmetic Centers
  • Hospitals
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Polynucleotides Injectable Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Growing demand for skin rejuvenation
      • 3.2.1.3. Shifting focus towards regenerative aesthetics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited access to the treatments
  • 3.3. Polynucleotides Injectable Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Polynucleotides Injectable Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Polynucleotides Injectable Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Eyes
      • 4.4.1.1. Eyes market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Lips
      • 4.4.2.1. Lips market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Forehead
      • 4.4.3.1. Forehead market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Jawline & Cheekbones
      • 4.4.4.1. Jawline & Cheekbones market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Polynucleotides Injectable Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Polynucleotides Injectable Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. MedSpas
      • 5.4.1.1. MedSpas market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Aesthetic & Cosmetic Centers
      • 5.4.2.1. Aesthetic & cosmetic centers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hospitals
      • 5.4.3.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Polynucleotides Injectable Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. North America
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Denmark
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Norway
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. PHARMA RESEARCH
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Others benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. BIOPLUS CO., LTD.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Others benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. LG Chem
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Others benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. AMEELA
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Others benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Mastelli
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Others benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Others benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Promoitalia Laboratories
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Others benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Fox Pharma
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Others benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. BR Pharm
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Others benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. DermFocus
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Others benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 10 Mexico polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 13 Europe polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 15 Germany polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 17 UK polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 19 France polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 21 Italy polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 23 Spain polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 25 Denmark polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 27 Sweden polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 29 Norway polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 33 China polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 34 China polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 36 Japan polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 38 India polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 40 South Korea polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Australia polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 42 Australia polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Thailand polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 44 Thailand polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 46 Latin America polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Brazil polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 48 Brazil polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Argentina polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 51 MEA polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 54 South Africa polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Africa polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 58 UAE polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Polynucleotides Injectable market: market outlook
  • Fig. 14 Polynucleotides Injectable competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Polynucleotides Injectable market driver impact
  • Fig. 20 Polynucleotides Injectable market restraint impact
  • Fig. 21 Polynucleotides Injectable market strategic initiatives analysis
  • Fig. 22 Polynucleotides Injectable market: application movement analysis
  • Fig. 23 Polynucleotides Injectable market: application outlook and key takeaways
  • Fig. 24 Eyes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Lips market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Forehead market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Jawline & cheekbones market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Polynucleotides Injectable market: end use movement analysis
  • Fig. 30 Polynucleotides Injectable market: end use outlook and key takeaways
  • Fig. 31 MedSpas market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Aesthetic & Cosmetic centers market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Global Polynucleotides Injectable market: Regional movement analysis
  • Fig. 35 Global Polynucleotides Injectable market: Regional outlook and key takeaways
  • Fig. 36 Global Polynucleotides Injectable market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. key country dynamics
  • Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Canada key country dynamics
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico key country dynamics
  • Fig. 50 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 UK key country dynamics
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Germany key country dynamics
  • Fig. 56 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 France key country dynamics
  • Fig. 58 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Italy key country dynamics
  • Fig. 60 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Spain key country dynamics
  • Fig. 62 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Denmark key country dynamics
  • Fig. 64 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Sweden key country dynamics
  • Fig. 66 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Norway key country dynamics
  • Fig. 68 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Australia key country dynamics
  • Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Thailand key country dynamics
  • Fig. 82 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Brazil key country dynamics
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Argentina key country dynamics
  • Fig. 88 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 South Africa key country dynamics
  • Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Saudi Arabia key country dynamics
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 UAE key country dynamics
  • Fig. 96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Kuwait key country dynamics
  • Fig. 98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- Polynucleotides Injectable market